Lourd Capital Raised Holding in Enbridge (ENB) by $311,581 as Market Valuation Declined; As Abbott Laboratories (ABT) Stock Price Rose, Holder Beach Investment Management Has Trimmed Stake by $566,813

June 24, 2018 - By Marguerite Chambers

Abbott Laboratories (NYSE:ABT) Logo

Beach Investment Management Llc decreased its stake in Abbott Laboratories (ABT) by 40.38% based on its latest 2018Q1 regulatory filing with the SEC. Beach Investment Management Llc sold 9,607 shares as the company’s stock rose 3.04% while stock markets declined. The institutional investor held 14,183 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $850,000, down from 23,790 at the end of the previous reported quarter. Beach Investment Management Llc who had been investing in Abbott Laboratories for a number of months, seems to be less bullish one the $108.59 billion market cap company. The stock increased 0.31% or $0.19 during the last trading session, reaching $61.94. About 5.00M shares traded. Abbott Laboratories (NYSE:ABT) has risen 41.91% since June 24, 2017 and is uptrending. It has outperformed by 29.34% the S&P500. Some Historical ABT News: 23/03/2018 – ABBOTT LABORATORIES’ ALERE TO PAY $33.2 MILLION TO RESOLVE U.S. JUSTICE DEPARTMENT PROBE; 18/05/2018 – ABBOTT: EXPLOSIVE DEVICES APPARENTLY WERE MADE BY THE SHOOTER; 28/03/2018 – Abbott has invested an undisclosed amount in Bigfoot Biomedical, a start-up creating diabetes care devices and systems; 19/03/2018 – ABBOTT’S MITRACLIP THERAPY GETS NATIONAL REIMBURSEMENT IN JAPAN; 31/05/2018 – ABBOTT LABORATORIES – LAUNCH OF ITS AFINION 2 ANALYZER IN U.S; 22/03/2018 – Global Transcatheter Aortic Valve lmplantation (TAVI) Market Analysis & Outlook 2018-2022 with Profiles of Abbott Laboratories, Boston Scientific, Edwards Lifesciences & Medtronic – ResearchAndMarkets; 30/05/2018 – HoustonChronicle: Sources: Abbott wants more armed guards, mental health services to prevent school shootings; 17/04/2018 – FDA: Certain Implantable Cardiac Devices by Abbott (formerly St. Jude Medical): FDA Safety Communication – Battery Performance; 23/04/2018 – Sanquin Selects Abbott’s “Alinity(TM) S” Solution for Blood and Plasma Screening; 23/05/2018 – ABBOTT – NEWEST GENERATION OF LEADING HEART STENT NOW APPROVED IN U.S. FOR PEOPLE WITH CORONARY ARTERY DISEASE

Lourd Capital Llc increased its stake in Enbridge Inc (ENB) by 50.47% based on its latest 2018Q1 regulatory filing with the SEC. Lourd Capital Llc bought 10,051 shares as the company’s stock declined 7.90% with the market. The institutional investor held 29,964 shares of the natural gas distribution company at the end of 2018Q1, valued at $943,000, up from 19,913 at the end of the previous reported quarter. Lourd Capital Llc who had been investing in Enbridge Inc for a number of months, seems to be bullish on the $55.05B market cap company. The stock increased 1.50% or $0.47 during the last trading session, reaching $31.73. About 3.60 million shares traded. Enbridge Inc. (NYSE:ENB) has declined 20.51% since June 24, 2017 and is downtrending. It has underperformed by 33.08% the S&P500. Some Historical ENB News: 10/05/2018 – ENBRIDGE LOOKING FOR EN BLOC SALE ON CANADIAN MIDSTREAM ASSETS; 16/03/2018 – ENBRIDGE INC – DOES NOT EXPECT A MATERIAL IMPACT TO PREVIOUSLY DISCLOSED FINANCIAL GUIDANCE OVER 2018-2020 HORIZON DUE TO FERC REVISED STATEMENTS; 09/05/2018 – Enbridge receives bids as high as C$4.5 bln for Canada midstream assets; 09/05/2018 – Enbridge To Sell Midcoast Operating, L.P. and Its Subsidiaries to AL Midcoast Holdings; 09/05/2018 – ENBRIDGE FUND TO SELL 49% STAKE IN RENEWABLE POWER ASSETS; 09/04/2018 – SIZE SET: Enbridge C$750m 60NC10 Fxd-to-Floating Rate Sub Notes; 10/05/2018 – ENBRIDGE WOULD EXPAND ASSET-SALE PROGRAM IF IT SEES GOOD VALUES; 07/03/2018 – ENBRIDGE CEO AL MONACO SPEAKS IN INTERVIEW AT CERAWEEK; 09/05/2018 – Enbridge to Sell 49 Percent of its Interests in Select Renewable Power Assets for $1.75 Billion; 05/04/2018 – Kevin Orland: Enbridge is seeking to cut its stake in a German offshore wind project, sources say via @markets by @ahirtens

Among 17 analysts covering Enbridge Inc. (NYSE:ENB), 7 have Buy rating, 0 Sell and 10 Hold. Therefore 41% are positive. Enbridge Inc. had 27 analyst reports since August 4, 2015 according to SRatingsIntel. Citigroup reinitiated the shares of ENB in report on Wednesday, January 18 with “Neutral” rating. As per Thursday, September 1, the company rating was initiated by Bank of America. BMO Capital Markets maintained it with “Outperform” rating and $59 target in Thursday, June 14 report. The firm has “Market Perform” rating by Wells Fargo given on Monday, April 3. Canaccord Genuity initiated the stock with “Buy” rating in Monday, March 7 report. RBC Capital Markets maintained Enbridge Inc. (NYSE:ENB) on Friday, October 9 with “Outperform” rating. The firm earned “Neutral” rating on Thursday, February 4 by Credit Suisse. The stock of Enbridge Inc. (NYSE:ENB) has “Outperform” rating given on Friday, October 23 by BMO Capital Markets. Morgan Stanley maintained it with “Equal-Weight” rating and $44 target in Friday, July 14 report. The firm has “Sector Perform” rating by National Bank Canada given on Monday, July 18.

More notable recent Enbridge Inc. (NYSE:ENB) news were published by: Nasdaq.com which released: “Why This Time It May Be Different for Kinder Morgan Stock” on June 22, 2018, also Seekingalpha.com with their article: “Enbridge prefers tunnel or trench as options for Great Lakes pipeline” published on June 15, 2018, Fool.com published: “Is Enbridge Inc. a Buy?” on May 31, 2018. More interesting news about Enbridge Inc. (NYSE:ENB) were released by: Bizjournals.com and their article: “Underwater construction begins on cross-border section of natural gas pipeline” published on June 14, 2018 as well as Fool.com‘s news article titled: “2 Top Stocks in the Oil Patch” with publication date: June 23, 2018.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 107 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Thursday, October 19 by Citigroup. The firm earned “Overweight” rating on Thursday, September 28 by Barclays Capital. Jefferies maintained the stock with “Buy” rating in Thursday, July 14 report. The firm earned “Buy” rating on Tuesday, August 15 by Cowen & Co. The rating was maintained by Jefferies on Thursday, August 4 with “Buy”. The firm has “Overweight” rating given on Tuesday, January 2 by JP Morgan. The firm has “Outperform” rating given on Thursday, January 25 by Wells Fargo. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Deutsche Bank on Saturday, August 29. BMO Capital Markets maintained the stock with “Buy” rating in Wednesday, January 24 report. The firm has “Buy” rating given on Friday, July 21 by Deutsche Bank.

Since January 30, 2018, it had 1 buying transaction, and 20 insider sales for $22.32 million activity. $84,344 worth of Abbott Laboratories (NYSE:ABT) shares were sold by MANNING JOSEPH J. Watkin Jared also sold $183,579 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, March 7. Bracken Sharon J sold 2,100 shares worth $126,559. The insider Fussell Stephen R sold $3.36 million. $1.73M worth of Abbott Laboratories (NYSE:ABT) shares were sold by Blaser Brian J. Contreras Jaime sold 6,284 shares worth $375,381.

Investors sentiment decreased to 0.83 in Q1 2018. Its down 0.08, from 0.91 in 2017Q4. It worsened, as 44 investors sold ABT shares while 606 reduced holdings. 126 funds opened positions while 411 raised stakes. 1.22 billion shares or 0.54% more from 1.22 billion shares in 2017Q4 were reported. Oregon-based Northside Mngmt Limited Liability Company has invested 0.19% in Abbott Laboratories (NYSE:ABT). 115,175 were reported by Broderick Brian C. Wells Fargo & Mn reported 0.36% of its portfolio in Abbott Laboratories (NYSE:ABT). Folger Nolan Fleming Douglas Capital Mngmt reported 0.85% in Abbott Laboratories (NYSE:ABT). Wetherby Asset Management Inc owns 38,934 shares or 0.32% of their US portfolio. Macguire Cheswick And Tuttle Inv Counsel Limited Co reported 91,878 shares or 1.03% of all its holdings. Peavine Lc reported 21,600 shares or 0.66% of all its holdings. 20,222 were accumulated by Waverton Inv Mgmt. Vestor Capital Limited Co, a Illinois-based fund reported 220,588 shares. Salem Cap Management Inc holds 0.81% of its portfolio in Abbott Laboratories (NYSE:ABT) for 24,845 shares. Phocas Financial owns 4,360 shares for 0% of their portfolio. Pennsylvania-based Somerset Com has invested 1.05% in Abbott Laboratories (NYSE:ABT). 39,848 were reported by Kentucky Retirement Systems Insur Trust Fund. Glenview Commercial Bank Tru Dept holds 1.82% of its portfolio in Abbott Laboratories (NYSE:ABT) for 64,585 shares. Shine Investment Advisory holds 1,437 shares.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts